Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.

@article{Untch2010NeoadjuvantTW,
  title={Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.},
  author={Michael Untch and Mahdi Rezai and Sibylle Loibl and Peter A. Fasching and Jens B. Huober and Hans Tesch and Ingo Bauerfeind and Joern Hilfrich and Holger Eidtmann and Bernd Gerber and Claus Hanusch and Thorsten Kuehn and Andreas du Bois and Jens Uwe Blohmer and Christoph Thomssen and Serban Dan Costa and Christian Jackisch and Manfred Kaufmann and Keyur Mehta and Gunter von Minckwitz},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2010},
  volume={28 12},
  pages={2024-31}
}
PURPOSE Trastuzumab, a humanized antibody against the human epidermal growth factor receptor type 2 (HER2), has shown high efficacy in breast cancer. We prospectively investigated its efficacy given simultaneously with anthracycline-taxane-based neoadjuvant chemotherapy. PATIENTS AND METHODS Patients with operable or locally advanced, HER2-positive tumors were treated preoperatively with four cycles of epirubicin/cyclophosphamide followed by four cycles of docetaxel with or without capecitabine… CONTINUE READING